Balanced news tone
News Sentiment
AAPG sentiment intelligence
Ascentage Pharma Group International news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
56
Balanced news tone
57 relevant articles
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+7.9% over one week, +13.5% over four weeks, trend inactive, and below fair value.
Ascentage Pharma (AAPG) Edges Higher, Testing Key Resistance Zone - Trend Reversal Picks
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
78/100 classification
One-week reaction
7.9%
Price confirming higher
Trend fit
Trend inactive
13.5% over four weeks
Fair value
-27.9%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
12
Neutral
44
Negative
1
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
DonanımHaber
Direct company coverage
Ascentage Pharma (AAPG) Edges Higher, Testing Key Resistance Zone - Trend Reversal Picks
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jul 2026 18:40
- Source
- DonanımHaber
Zacks Investment Research
Direct company coverage
How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23%
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jul 2026 13:03
- Source
- Zacks Investment Research
Insider Monkey
Direct company coverage
Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development
Ascentage Pharma Group Internat (NASDAQ:AAPG) is gaining attention in cancer drug development, with Oppenheimer initiating coverage with an Outperform rating and a $45 price target. The company recently presented positive clinical updates at ASCO and EHA2026 for its core programs
- Tone
- Positive 77/100
- Event
- Analyst action
- Published
- 30 Jun 2026 09:20
- Source
- Insider Monkey
TradingView
Direct company coverage
Price to sales forward of Ascentage Pharma Group International – HKEX:6855
The article provides a financial data point for Ascentage Pharma Group International (HKEX:6855), specifically its "Price to sales forward" metric. It appears to be a stub or a data-focused page from TradingView, showing the company's market and financial status.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 20:11
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Ascentage Pharma Group International – HKEX:6855
This article provides the forward Enterprise Value to EBITDA for Ascentage Pharma Group International (HKEX:6855). It highlights financial data available on TradingView for the Hong Kong-listed pharmaceutical company. The content appears to be a financial data point from a larger
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 08:39
- Source
- TradingView
The Globe and Mail
Direct company coverage
Ascentage Pharma Grants New RSUs to 453 Employees Under 2021 Scheme
Ascentage Pharma Group International has granted 440,743 Restricted Share Units (RSUs) to 453 employees under its 2021 RSU Scheme. These RSUs, representing about 0.12% of the company's issued share capital, are intended to incentivize employees and have received listing approval
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 00:10
- Source
- The Globe and Mail
TradingView
Direct company coverage
Price to sales forward of Ascentage Pharma Group International - American Depository Shares – NASDAQ:AAPG
This article focuses on the "Price to sales forward" metric for Ascentage Pharma Group International (NASDAQ: AAPG). The content provided is primarily navigational and structural, indicating a financial data page rather than an analytical piece. It mentions the stock ticker AAPG
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 23:11
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Ascentage Pharma Group International – HKEX:6855
This article displays the "Price to earnings forward" financial data for Ascentage Pharma Group International (HKEX:6855) on TradingView. It shows that the market is currently closed with no trades recorded for this specific financial metric. The content includes general market i
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 13:09
- Source
- TradingView
TradingView
Direct company coverage
Ascentage Pharma Group International - American Depository Shares
This article provides a financial overview of Ascentage Pharma Group International - American Depository Shares (NASDAQ: AAPG), focusing on its enterprise value to EBITDA forward. It indicates that the market is currently closed with no trades. The content is presented within the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 04:09
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Ascentage Pharma Group International – HKEX:6855
The article focuses on the "Enterprise value to EBIT forward" metric for Ascentage Pharma Group International (HKEX:6855) as presented on TradingView. It provides a brief financial overview of the company on the Hong Kong Exchange, indicating the market status at the time of publ
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 23:43
- Source
- TradingView
TradingView
Direct company coverage
6855 Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast for Ascentage Pharma Group International (6855) stock, including price targets from analysts, historical performance, and key financial metrics. It also addresses frequently asked questions about the company's stock price, volatility, mar
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 27 Jun 2026 07:11
- Source
- TradingView
TradingView
Direct company coverage
Ascentage Pharma Group International Actuals & Estimates (OTC:ASPHF)
This article provides an overview of Ascentage Pharma Group International (ASPHF), detailing its current stock price, market capitalization, earnings estimates, and revenue figures. It includes analyst forecasts, historical price data, and information on the company's financial r
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 02:10
- Source
- TradingView
TradingView
Direct company coverage
Ascentage Pharma Group International Actuals & Estimates (HKEX:6855)
This article provides an overview of Ascentage Pharma Group International (HKEX:6855) stock performance, financial data, and analyst forecasts. It details the current stock price, historical highs and lows, volatility, market capitalization, and upcoming earnings report. The comp
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 02:10
- Source
- TradingView
TradingView
Direct company coverage
36X Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Ascentage Pharma Group International (36X) based on analyst opinions. It details analyst estimates for future stock prices, past financial performance including earnings and revenue, and key financial metrics like EBITDA. The
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 19:09
- Source
- TradingView
TradingView
Direct company coverage
AAPG Forecast — Price Target — Prediction for 2027
The TradingView forecast for Ascentage Pharma Group International (AAPG) indicates a price target of 46.78. This target is based on analyses from 9 analysts over the past three months, though specific maximum and minimum estimates were not provided. The report also includes secti
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 26 Jun 2026 10:09
- Source
- TradingView
TradingView
Direct company coverage
Ascentage Pharma Group International Unsponsored ADR Actuals & Estimates (NASDAQ:AAPG)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 08:27
- Source
- TradingView
dars.gov.et
Direct company coverage
Ascentage Pharma (AAPG) Hovers Near Resistance as Traders Await Catalysts - NAAIM Exposure
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jun 2026 07:00
- Source
- dars.gov.et
TradingKey
Direct company coverage
Ascentage Pharma Group International (AAPG) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides historical data on dividends and stock splits for Ascentage Pharma Group International (AAPG). It notes that AAPG has distributed no dividends over the past five years and has no recorded stock split events. The page also includes current stock price informa
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 11:09
- Source
- TradingKey
TradingKey
Direct company coverage
Ascentage Pharma Group International (AAPG) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Ascentage Pharma Group International's (AAPG) shareholder structure, listing major individual and institutional holders. It highlights top shareholders like Point72 (DIFC) Ltd and Citadel Advisors LLC, along with institutional holding
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 10:09
- Source
- TradingKey
TradingKey
Direct company coverage
Ascentage Pharma Group International (AAPG) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Ascentage Pharma Group International (AAPG), detailing analyst ratings and target prices. Based on 9 analysts, the stock has a "Buy" trend with a target price of $47.750, indicating a potential upside of 178.91%. The article also inc
- Tone
- Positive 77/100
- Event
- Earnings
- Published
- 19 Jun 2026 03:39
- Source
- TradingKey
TradingKey
Direct company coverage
Ascentage Pharma Group International (AAPG) Valuation: PE, PB & Fair Value Analysis
This article provides a brief valuation analysis for Ascentage Pharma Group International (AAPG), detailing its stock performance and market capitalization. It highlights that key valuation data such as P/E, P/B, P/S, and P/CF ratios have not yet been disclosed by the company. Th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 17:40
- Source
- TradingKey
Stock Titan
Direct company coverage
Ascentage Pharma (NASDAQ: AAPG) posts new CML, Ph+ ALL and CLL data
Ascentage Pharma released extensive new clinical data for its cancer drugs olverembatinib and lisaftoclax from 17 presentations at the EHA2026 hematology congress. The data showed promising results in chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphobl
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 15 Jun 2026 11:39
- Source
- Stock Titan
grafa.com
Direct company coverage
Ascentage Pharma details 17 clinical updates at EHA 2026
Ascentage Pharma (NASDAQ: AAPG) presented 17 clinical updates at the EHA2026 Congress in Copenhagen, detailing positive oncology data for its core therapeutic candidates, olverembatinib and lisaftoclax. The data showed high response rates and manageable safety profiles across var
- Tone
- Positive 75/100
- Event
- Macro sensitivity
- Published
- 15 Jun 2026 09:01
- Source
- grafa.com
Stock Titan
Direct company coverage
Chemo-free Ascentage leukemia combo posts 88.9% response in children
Ascentage Pharma presented 17 clinical updates at the EHA2026 Congress, showcasing data for olverembatinib and lisaftoclax in various hematologic malignancies. A chemotherapy-free combination of olverembatinib and lisaftoclax in pediatric patients with relapsed/refractory Ph+ ALL
- Tone
- Positive 76/100
- Event
- Market update
- Published
- 15 Jun 2026 01:39
- Source
- Stock Titan
The Manila Times
Direct company coverage
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
Ascentage Pharma presented seventeen clinical updates on its core assets, olverembatinib and lisaftoclax, at the 31st Congress of the European Hematology Association (EHA2026). The presentations showcased positive data for olverembatinib in treating chronic myeloid leukemia (CML)
- Tone
- Positive 90/100
- Event
- Market update
- Published
- 15 Jun 2026 00:09
- Source
- The Manila Times
Simply Wall Street
Direct company coverage
Ascentage Pharma (SEHK:6855) Stock After New ASCO 2026 Data A Fresh Look At Valuation
Ascentage Pharma's stock gained 3.93% following new ASCO 2026 data presentations for olverembatinib and alrizomadlin, despite a significant year-to-date decline. The company is considered undervalued with a narrative fair value of HK$71.81 against a current price of HK$34.9, larg
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jun 2026 02:40
- Source
- Simply Wall Street
The Globe and Mail
Direct company coverage
Ascentage Pharma Trustee Buys Shares to Fund 2022 RSU Incentive Scheme
Ascentage Pharma Group International's 2022 restricted share unit (RSU) scheme trustee recently purchased 190,000 shares on the market, costing approximately HK$33.78 per share. These shares, representing about 0.0509% of issued capital, are intended solely to satisfy RSUs upon v
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 02:08
- Source
- The Globe and Mail
Moomoo
Direct company coverage
Ascentage Pharma Group International (06855): The trustee has purchased 110,000 shares for the purposes of the 2022 Restricted Share Unit Plan.
The trustee of Ascentage Pharma Group International has acquired 110,000 shares, costing approximately HK$1.734 million. These shares were purchased for the purposes of the company's 2022 Restricted Share Unit Plan. The accumulation of these shares reflects ongoing activity relat
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 13:09
- Source
- Moomoo
Investing.com
Direct company coverage
B.Riley initiates Ascentage Pharma stock with buy, $45 target
B.Riley has initiated coverage on Ascentage Pharma Group International (NASDAQ:AAPG) with a Buy rating and a $45 price target, highlighting the company's two approved hematology-oncology products and robust pipeline. Ascentage Pharma reported $82 million in revenue in 2025, a 90%
- Tone
- Positive 93/100
- Event
- Analyst action
- Published
- 11 Jun 2026 02:39
- Source
- Investing.com